BIS vs. NDAQ
Compare and contrast key facts about ProShares UltraShort Nasdaq Biotechnology (BIS) and Nasdaq, Inc. (NDAQ).
BIS is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (-200%). It was launched on Apr 7, 2010.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIS or NDAQ.
Performance
BIS vs. NDAQ - Performance Comparison
Returns By Period
In the year-to-date period, BIS achieves a -0.78% return, which is significantly lower than NDAQ's 39.27% return. Over the past 10 years, BIS has underperformed NDAQ with an annualized return of -21.22%, while NDAQ has yielded a comparatively higher 20.50% annualized return.
BIS
-0.78%
14.98%
3.75%
-26.18%
-20.96%
-21.22%
NDAQ
39.27%
7.78%
29.18%
48.83%
19.97%
20.50%
Key characteristics
BIS | NDAQ | |
---|---|---|
Sharpe Ratio | -0.68 | 2.65 |
Sortino Ratio | -0.85 | 3.65 |
Omega Ratio | 0.91 | 1.48 |
Calmar Ratio | -0.25 | 2.34 |
Martin Ratio | -0.83 | 15.76 |
Ulcer Index | 29.57% | 3.18% |
Daily Std Dev | 35.92% | 18.94% |
Max Drawdown | -99.77% | -68.48% |
Current Drawdown | -99.72% | -0.10% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Correlation
The correlation between BIS and NDAQ is -0.41. This indicates that the assets' prices tend to move in opposite directions. Negative correlation can be particularly beneficial for diversification and risk management, as one asset may offset the losses of the other during market fluctuations.
Risk-Adjusted Performance
BIS vs. NDAQ - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares UltraShort Nasdaq Biotechnology (BIS) and Nasdaq, Inc. (NDAQ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIS vs. NDAQ - Dividend Comparison
BIS's dividend yield for the trailing twelve months is around 3.72%, more than NDAQ's 1.15% yield.
TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
ProShares UltraShort Nasdaq Biotechnology | 3.72% | 1.75% | 0.00% | 0.00% | 0.44% | 2.10% | 0.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Nasdaq, Inc. | 1.15% | 1.48% | 1.27% | 1.00% | 1.46% | 1.73% | 2.08% | 1.90% | 1.80% | 1.55% | 1.21% | 1.31% |
Drawdowns
BIS vs. NDAQ - Drawdown Comparison
The maximum BIS drawdown since its inception was -99.77%, which is greater than NDAQ's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for BIS and NDAQ. For additional features, visit the drawdowns tool.
Volatility
BIS vs. NDAQ - Volatility Comparison
ProShares UltraShort Nasdaq Biotechnology (BIS) has a higher volatility of 13.19% compared to Nasdaq, Inc. (NDAQ) at 5.29%. This indicates that BIS's price experiences larger fluctuations and is considered to be riskier than NDAQ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.